Los puntos clave no están disponibles para este artículo en este momento.
Further evaluation of tafamidis therapy in a larger patient cohort with transthyretin amyloid cardiomyopathy is warranted to determine the optimal therapeutic strategy.
Nakamura et al. (Mon,) studied this question.